GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial
March 29, 2021Sales and Marketing COVID-19, GSK, Phase III trial, covid-19 treatment, vir
GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the …
Janssen’s multiple sclerosis treatment recommended by EMA
March 29, 2021Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis
Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …
BATM develops molecular diagnostics test for tuberculosis
March 29, 2021Sales and Marketing TB, testing
BATM have announced that it has developed a new method for the rapid and comprehensive diagnosis of tuberculosis (TB), which …
gaitQ awarded NIHR grant for Parkinson’s wearable tech
March 29, 2021Sales and Marketing Parkinson's, medical technology
The UK’s National Institute for Health Research (NIHR) has awarded a £135,000 grant to gaitQ, a spin-off from the University …
Pharmafile.com’s top 10 news stories of the week
March 26, 2021Medical Communications AstraZeneca vaccine, COVID-19, covid 19 news, covid-19 news, news, news roundup, starpharma
In the last week, a number of new developments have made the news; for COVID-19, Starpharma will begin to sell …
FDA approve Astellas’s Myrbetriq treatment for bladder dysfunction
March 26, 2021Medical Communications Astellas Pharma, FDA, Ida approval
The FDA have approved a new indication for Astellas Pharma’s Myrbetriq and Myrbetriq Granules to treat neurogenic detrusor overactivity (NDO), …
Astellas Pharma and Seagen cancer treatment gets MAA acceptance from EMA
March 26, 2021Medical Communications EMA, oncology
Astellas Pharma and Seagen Inc. have announced that the EMA has accepted their marketing authorisation application (MAA) for enfortumab vedotin, …
Novavax delays 100 million vaccines to the EU
March 26, 2021Medical Communications COVID-19, EU, Vaccine
Novavax is delaying the signing of a contract to supply COVID-19 vaccines to the EU, as the company warned it …
Pfizer begins COVID-19 vaccine testing on young children
March 26, 2021Medical Communications COVID-19, Pfizer, Vaccine
Pfizer have begun testing its COVID-19 vaccine on children under the age of 12, with the trials’ first participants, a …
Starpharma to sell COVID-fighting nose spray in UK
March 25, 2021COVID-19
Australian biotech company, Starpharma, has announced a deal with LloydsPharmacy to sell its COVID-fighting antiviral nasal spray, Viraleze, in the …
Merck and UCLA find new COVID-19 treatment candidate
March 25, 2021COVID-19, Merck, berzosertib, covid-19 treatment, ucla
Merck (MSD in the UK), the UCLA, and other universities from the US and Germany have uncovered a compound that …
AstraZeneca vaccine found to be 3% less effective after further trial analysis
March 25, 2021AstraZeneca, AstraZeneca vaccine, COVID-19, COVID-19 vaccine, Vaccine
AstraZeneca have revised their findings from the US study AZD1222 of their COVID-19 vaccine, announcing a 76% efficacy against symptoms …
NHS agrees on MSD interim colorectal cancer treatment
March 25, 2021COVID-19, Cancer, MSD, NHS
MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …
AstraZeneca and J&J COVID-19 vaccines face viral vector shortage
March 25, 2021Astrazenaca, COVID-19, Johnson & Johnson, Vaccine
Both AstraZeneca and J&J face major manufacturing deficiencies for their recombinant vector COVID-19 vaccines, forcing competition over limited production capacity …
Pharmafile.com’s weekly COVID-19 news round-up
March 24, 2021Research and Development COVID-19, covid 19 news, covid-19 news, news roundup
The past week has seen plenty of positive COVID-19 news; the Oxford-AstraZeneca vaccine was deemed safe and effective by the …
Roche’s drug cocktail reduces hospitalisation due to COVID-19 in Phase III trial
March 24, 2021Research and Development COVID-19, Roche, covid-19 treatment
Roche’s antibody drug combination of casirivimab and imdevimab has shown to reduce hospitalisation or death by 70% in non-hospitalised patients …
Pfizer and Myovant’s menstrual blood loss treatment reports 78% effectiveness
March 24, 2021Research and Development Myovant, Pfizer, Phase III trial, fibroids, uterine fibroids
Pfizer and Myovant Science’s relugolix treatment to reduce menstrual blood loss in women with uterine fibroids has shown promising results …
Novo Nordisk obesity treatment successful in clinical trials
March 24, 2021Research and Development Novo Nordisk, obesity
New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …
Guerbet see positive Phase III results for MRI agent
March 24, 2021Research and Development MRI
Medical imaging company, Guerbet, have announced the success of its Phase III study into the safety and efficacy of Gadopiclenol, …
Zealand’s Zegalogue treatment for hypoglycemia approved by FDA
March 23, 2021Manufacturing and Production FDA, Zealand Pharma, Zegalogue
The FDA have approved Zealand Pharma’s Zegalogue therapy for the treatment of severe hypoglycemia in patients with diabetes.
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
